What is Aphena?
Headquartered in Cookeville, Tennessee, Aphena Pharma operates as a comprehensive solution provider for the pharmaceutical, dietary supplement, and animal health industries. The company distinguishes itself through high-precision packaging and manufacturing services, catering to a diverse client base that includes consumer health brands and biologics developers. By maintaining rigorous quality standards and specialized facilities, Aphena has established itself as a critical link in the pharmaceutical supply chain, enabling its partners to bring complex products to market with greater efficiency and regulatory compliance.
How much funding has Aphena raised?
Aphena has raised a total of $22.8M across 8 funding rounds:
Multiple Rounds
$11.9M
Debt
$4.1M
Private Equity
$2.1M
Private Equity
$3.6M
Unspecified
$134K
Debt
$1M
Private Equity (2010): $1.2M, investors not publicly disclosed
Private Equity (2010): $5.8M led by Enhanced Equity Funds
Private Equity (2010): $4.9M supported by Enhanced Equity Funds
Debt (2011): $4.1M featuring Enhanced Equity Funds
Private Equity (2012): $2.1M backed by Enhanced Equity Funds
Private Equity (2013): $3.6M with participation from Enhanced Equity Funds
Unspecified (2014): $134K led by Maryland Department of Business and Economic Development
Debt (2020): $1M supported by PPP
Key Investors in Aphena
Enhanced Equity Funds
A private equity firm specializing in healthcare investments, focusing on value creation through organizational development and strategic acquisitions for smaller companies.
Maryland Department of Business and Economic Development
A government entity dedicated to fostering economic growth and providing resources for business development within the State of Maryland.
PPP
Public-Private Partnership
What's next for Aphena?
Looking ahead, Aphena is well-positioned to leverage its historical funding success to pursue further market penetration. The strategic deployment of capital will likely focus on enhancing technological capabilities within its packaging lines and potentially exploring inorganic growth opportunities through targeted acquisitions. As the pharmaceutical and medical device sectors continue to demand higher levels of outsourcing, Aphena's established infrastructure and proven track record of institutional backing provide a robust foundation for sustained long-term growth and operational excellence.
See full Aphena company page
